Avibactam Sodium

CHEMBL2107817 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

287.2 g/mol

LogP

—

Phase

4

The sodium salt of avibactam, formulated for intravenous use in combination with ceftazidime to treat serious infections caused by drug-resistant Gram-negative bacteria. By protecting the partner antibiotic from enzymatic destruction, it restores its bactericidal activity.

الوزن الجزيئي

287,2300 g/mol

TPSA

141,00 Å²

المجالات العلاجية

Infectious Disease

آلية العمل

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)[O-].[Na+]

InChI

InChI=1S/C7H11N3O6S.Na/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);/q;+1/p-1/t4-,5+;/m1./s1

Molecular Formula

C7H10N3NaO6S

HBD / HBA

1 / 6

الروابط القابلة للدوران

3

الذرات الثقيلة

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

The sodium salt of avibactam, formulated for intravenous use in combination with ceftazidime to treat serious infections caused by drug-resistant Gram-negative bacteria. By protecting the partner antibiotic from enzymatic destruction, it restores its bactericidal activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Avibactam Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107817. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 24944097. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Avibactam Sodium على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C7H10N3NaO6S

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.